ID   RN19A_HUMAN             Reviewed;         838 AA.
AC   Q9NV58; A3KCU9; Q52LG1; Q9H5H9; Q9H8M8; Q9UFG0; Q9UFX6; Q9Y4Y1;
DT   11-JUL-2001, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   10-MAY-2017, entry version 155.
DE   RecName: Full=E3 ubiquitin-protein ligase RNF19A;
DE            EC=2.3.2.- {ECO:0000250|UniProtKB:O60260};
DE   AltName: Full=Double ring-finger protein;
DE            Short=Dorfin;
DE   AltName: Full=RING finger protein 19A;
DE   AltName: Full=p38;
GN   Name=RNF19A; Synonyms=RNF19;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH
RP   UBE2L3 AND UBE2L6, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Spinal cord;
RX   PubMed=11237715; DOI=10.1006/bbrc.2001.4414;
RA   Niwa J., Ishigaki S., Doyu M., Suzuki T., Tanaka K., Sobue G.;
RT   "A novel centrosomal ring-finger protein, dorfin, mediates ubiquitin
RT   ligase activity.";
RL   Biochem. Biophys. Res. Commun. 281:706-713(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-89 (ISOFORM 3).
RA   Kim T., Huh J., Kim H.;
RT   "Expression and promoter activity of MaLR element of Dorfin gene
RT   related to Parkinson disease.";
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 426-838 (ISOFORM 1), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 142-838 (ISOFORM 2).
RC   TISSUE=Hepatoma, Ovarian carcinoma, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 422-824 (ISOFORM 1), AND INTERACTION
RP   WITH SP1.
RC   TISSUE=Colon;
RX   PubMed=10976766; DOI=10.1023/A:1007177623283;
RA   Gunther M., Laithier M., Brison O.;
RT   "A set of proteins interacting with transcription factor Sp1
RT   identified in a two-hybrid screening.";
RL   Mol. Cell. Biochem. 210:131-142(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 524-838 (ISOFORM 1).
RC   TISSUE=Fetal kidney, and Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SOD1.
RX   PubMed=12145308; DOI=10.1074/jbc.M206559200;
RA   Niwa J., Ishigaki S., Hishikawa N., Yamamoto M., Doyu M., Murata S.,
RA   Tanaka K., Taniguchi N., Sobue G.;
RT   "Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated
RT   neurotoxicity.";
RL   J. Biol. Chem. 277:36793-36798(2002).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SNCAIP.
RX   PubMed=12750386; DOI=10.1074/jbc.M302763200;
RA   Ito T., Niwa J., Hishikawa N., Ishigaki S., Doyu M., Sobue G.;
RT   "Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1.";
RL   J. Biol. Chem. 278:29106-29114(2003).
RN   [9]
RP   FUNCTION, INTERACTION WITH VCP, MUTAGENESIS OF CYS-132 AND CYS-135,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=15456787; DOI=10.1074/jbc.M406683200;
RA   Ishigaki S., Hishikawa N., Niwa J., Iemura S., Natsume T., Hori S.,
RA   Kakizuka A., Tanaka K., Sobue G.;
RT   "Physical and functional interaction between dorfin and valosin-
RT   containing protein that are colocalized in ubiquitylated inclusions in
RT   neurodegenerative disorders.";
RL   J. Biol. Chem. 279:51376-51385(2004).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH CASR AND VCP.
RX   PubMed=16513638; DOI=10.1074/jbc.M513552200;
RA   Huang Y., Niwa J., Sobue G., Breitwieser G.E.;
RT   "Calcium-sensing receptor ubiquitination and degradation mediated by
RT   the E3 ubiquitin ligase dorfin.";
RL   J. Biol. Chem. 281:11610-11617(2006).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from
CC       E2 ubiquitin-conjugating enzymes UBE2L3 and UBE2L6 in the form of
CC       a thioester and then directly transfers the ubiquitin to targeted
CC       substrates, such as SNCAIP or CASR. Specifically ubiquitinates
CC       pathogenic SOD1 variants, which leads to their proteasomal
CC       degradation and to neuronal protection.
CC       {ECO:0000269|PubMed:11237715, ECO:0000269|PubMed:12145308,
CC       ECO:0000269|PubMed:12750386, ECO:0000269|PubMed:15456787,
CC       ECO:0000269|PubMed:16513638}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000250|UniProtKB:O60260}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with UBE2L3 and UBE2L6. Interacts with
CC       transcription factor Sp1. Interacts with VCP, CASR, SNCAIP and
CC       with some SOD1 variants which cause amyotrophic lateral sclerosis,
CC       but not with wild-type SOD1. {ECO:0000269|PubMed:10976766,
CC       ECO:0000269|PubMed:11237715, ECO:0000269|PubMed:12145308,
CC       ECO:0000269|PubMed:12750386, ECO:0000269|PubMed:15456787,
CC       ECO:0000269|PubMed:16513638}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:11237715,
CC       ECO:0000269|PubMed:12145308, ECO:0000269|PubMed:12750386,
CC       ECO:0000269|PubMed:15456787}. Note=Present in the hyaline
CC       inclusion bodies specifically found in motor neurons from
CC       amyotrophic lateral sclerosis patients. Present in the Lewy bodies
CC       specifically found in neurons from Parkinson disease patients.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9NV58-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NV58-2; Sequence=VSP_021010, VSP_021011;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q9NV58-3; Sequence=VSP_028631;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in
CC       heart. Ubiquitously expressed in the central nervous system.
CC       {ECO:0000269|PubMed:11237715}.
CC   -!- DOMAIN: Members of the RBR family are atypical E3 ligases. They
CC       interact with the E2 conjugating enzyme UBE2L3 and function like
CC       HECT-type E3 enzymes: they bind E2s via the first RING domain, but
CC       require an obligate trans-thiolation step during the ubiquitin
CC       transfer, requiring a conserved cysteine residue in the second
CC       RING domain. {ECO:0000250|UniProtKB:O60260}.
CC   -!- SIMILARITY: Belongs to the RBR family. RNF19 subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB14581.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAB15647.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB029316; BAB39353.1; -; mRNA.
DR   EMBL; BC093938; AAH93938.1; -; mRNA.
DR   EMBL; BC093940; AAH93940.1; -; mRNA.
DR   EMBL; AB271914; BAF48117.1; -; mRNA.
DR   EMBL; AK001774; BAA91900.1; -; mRNA.
DR   EMBL; AK023455; BAB14581.1; ALT_INIT; mRNA.
DR   EMBL; AK027070; BAB15647.1; ALT_INIT; mRNA.
DR   EMBL; AJ242975; CAB45132.1; -; mRNA.
DR   EMBL; AL110253; CAB53700.1; -; mRNA.
DR   EMBL; AL122096; CAB59264.1; -; mRNA.
DR   CCDS; CCDS6286.1; -. [Q9NV58-1]
DR   PIR; T34528; T34528.
DR   RefSeq; NP_001267468.1; NM_001280539.1. [Q9NV58-1]
DR   RefSeq; NP_056250.3; NM_015435.4. [Q9NV58-1]
DR   RefSeq; NP_904355.1; NM_183419.3. [Q9NV58-1]
DR   RefSeq; XP_005250910.1; XM_005250853.3. [Q9NV58-1]
DR   RefSeq; XP_016868791.1; XM_017013302.1. [Q9NV58-1]
DR   RefSeq; XP_016868792.1; XM_017013303.1. [Q9NV58-1]
DR   UniGene; Hs.292882; -.
DR   ProteinModelPortal; Q9NV58; -.
DR   SMR; Q9NV58; -.
DR   BioGrid; 117405; 13.
DR   IntAct; Q9NV58; 7.
DR   STRING; 9606.ENSP00000342667; -.
DR   iPTMnet; Q9NV58; -.
DR   PhosphoSitePlus; Q9NV58; -.
DR   DMDM; 116242764; -.
DR   MaxQB; Q9NV58; -.
DR   PaxDb; Q9NV58; -.
DR   PeptideAtlas; Q9NV58; -.
DR   PRIDE; Q9NV58; -.
DR   Ensembl; ENST00000341084; ENSP00000342667; ENSG00000034677. [Q9NV58-1]
DR   Ensembl; ENST00000519449; ENSP00000428968; ENSG00000034677. [Q9NV58-1]
DR   GeneID; 25897; -.
DR   KEGG; hsa:25897; -.
DR   UCSC; uc003yjj.3; human. [Q9NV58-1]
DR   CTD; 25897; -.
DR   DisGeNET; 25897; -.
DR   GeneCards; RNF19A; -.
DR   HGNC; HGNC:13432; RNF19A.
DR   HPA; CAB011455; -.
DR   HPA; HPA023652; -.
DR   MIM; 607119; gene.
DR   neXtProt; NX_Q9NV58; -.
DR   OpenTargets; ENSG00000034677; -.
DR   PharmGKB; PA162401601; -.
DR   eggNOG; KOG1815; Eukaryota.
DR   eggNOG; ENOG410XP9Y; LUCA.
DR   GeneTree; ENSGT00840000129738; -.
DR   HOVERGEN; HBG052073; -.
DR   InParanoid; Q9NV58; -.
DR   KO; K11972; -.
DR   OMA; SNMKINE; -.
DR   OrthoDB; EOG091G0503; -.
DR   PhylomeDB; Q9NV58; -.
DR   TreeFam; TF324777; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; RNF19A; human.
DR   GeneWiki; RNF19A; -.
DR   GenomeRNAi; 25897; -.
DR   PRO; PR:Q9NV58; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000034677; -.
DR   CleanEx; HS_RNF19A; -.
DR   ExpressionAtlas; Q9NV58; baseline and differential.
DR   Genevisible; Q9NV58; HS.
DR   GO; GO:0005813; C:centrosome; TAS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IBA:GO_Central.
DR   GO; GO:0008134; F:transcription factor binding; TAS:UniProtKB.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IBA:GO_Central.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; EXP:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0000209; P:protein polyubiquitination; IBA:GO_Central.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR031127; E3_UB_ligase_RBR.
DR   InterPro; IPR002867; IBR_dom.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR11685; PTHR11685; 1.
DR   Pfam; PF01485; IBR; 2.
DR   SMART; SM00647; IBR; 2.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Membrane; Metal-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transferase; Transmembrane;
KW   Transmembrane helix; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    838       E3 ubiquitin-protein ligase RNF19A.
FT                                /FTId=PRO_0000056061.
FT   TRANSMEM    368    388       Helical. {ECO:0000255}.
FT   TRANSMEM    424    444       Helical. {ECO:0000255}.
FT   ZN_FING     132    179       RING-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     199    264       IBR-type.
FT   ZN_FING     301    332       RING-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION      660    838       Interaction with CASR.
FT                                {ECO:0000269|PubMed:16513638}.
FT   ACT_SITE    316    316       {ECO:0000250|UniProtKB:Q9Y4X5}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1     31       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_028631.
FT   VAR_SEQ     572    604       RYSLSGESGTVSLGTVSDNASTKAMAGSILNSY -> AAVA
FT                                AAGRWAYSPATLRCRRSEELKNIHDSS (in isoform
FT                                2). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_021010.
FT   VAR_SEQ     605    838       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_021011.
FT   VARIANT     835    835       Q -> H (in dbSNP:rs9642785).
FT                                /FTId=VAR_028045.
FT   MUTAGEN     132    132       C->S: Abolishes interaction with VCP and
FT                                E3 ligase activity toward mutant SOD1;
FT                                when associated with S-135.
FT                                {ECO:0000269|PubMed:15456787}.
FT   MUTAGEN     135    135       C->S: Abolishes interaction with VCP and
FT                                E3 ligase activity toward mutant SOD1;
FT                                when associated with S-132.
FT                                {ECO:0000269|PubMed:15456787}.
FT   CONFLICT    645    645       H -> Y (in Ref. 1; BAB39353).
FT                                {ECO:0000305}.
FT   CONFLICT    744    744       S -> R (in Ref. 6; CAB53700).
FT                                {ECO:0000305}.
SQ   SEQUENCE   838 AA;  90696 MW;  00A7DED5023FDC06 CRC64;
     MQEQEIGFIS KYNEGLCVNT DPVSILTSIL DMSLHRQMGS DRDLQSSASS VSLPSVKKAP
     KKRRISIGSL FRRKKDNKRK SRELNGGVDG IASIESIHSE MCTDKNSIFS TNTSSDNGLT
     SISKQIGDFI ECPLCLLRHS KDRFPDIMTC HHRSCVDCLR QYLRIEISES RVNISCPECT
     ERFNPHDIRL ILSDDVLMEK YEEFMLRRWL VADPDCRWCP APDCGYAVIA FGCASCPKLT
     CGREGCGTEF CYHCKQIWHP NQTCDAARQE RAQSLRLRTI RSSSISYSQE SGAAADDIKP
     CPRCAAYIIK MNDGSCNHMT CAVCGCEFCW LCMKEISDLH YLSPSGCTFW GKKPWSRKKK
     ILWQLGTLVG APVGIALIAG IAIPAMIIGI PVYVGRKIHN RYEGKDVSKH KRNLAIAGGV
     TLSVIVSPVV AAVTVGIGVP IMLAYVYGVV PISLCRSGGC GVSAGNGKGV RIEFDDENDI
     NVGGTNTAVD TTSVAEARHN PSIGEGSVGG LTGSLSASGS HMDRIGAIRD NLSETASTMA
     LAGASITGSL SGSAMVNCFN RLEVQADVQK ERYSLSGESG TVSLGTVSDN ASTKAMAGSI
     LNSYIPLDKE GNSMEVQVDI ESKPSKFRHN SGSSSVDDGS ATRSHAGGSS SGLPEGKSSA
     TKWSKEATAG KKSKSGKLRK KGNMKINETR EDMDAQLLEQ QSTNSSEFEA PSLSDSMPSV
     ADSHSSHFSE FSCSDLESMK TSCSHGSSDY HTRFATVNIL PEVENDRLEN SPHQCSISVV
     TQTASCSEVS QLNHIAEEHG NNGIKPNVDL YFGDALKETN NNHSHQTMEL KVAIQTEI
//
